Evidence map›Paper›PMID 42363831›Full record

ArticleAntimicrobial agents and chemotherapy2026

Population pharmacokinetics of dalbavancin: external validation, model averaging, and implications for precision dosing in prolonged therapy.

Hamza Sayadi, Matthieu Gregoire, Yeleen Fromage, Marc Labriffe, Franck Maizaud, Caroline Monchaud, Cyrielle Codde, David Boutoille, Pierre Marquet, Jean-Baptiste Woillard

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hamza SayadiDepartment of Pharmacology, Toxicology and Pharmacovigilance, Dupuytren University Hospital (CHU Dupuytren), Limoges, France.
Matthieu GregoireClinical Pharmacology Department, Nantes University, Nantes University Hospital, Nantes, France.ORCID 0000-0003-1232-5761
Yeleen FromageINSERM CIC 1435, Dupuytren University Hospital (CHU Dupuytren), Limoges, France.
Marc LabriffeDepartment of Pharmacology, Toxicology and Pharmacovigilance, Dupuytren University Hospital (CHU Dupuytren), Limoges, France.
Franck MaizaudDepartment of Pharmacology, Toxicology and Pharmacovigilance, Dupuytren University Hospital (CHU Dupuytren), Limoges, France.
Caroline MonchaudDepartment of Pharmacology, Toxicology and Pharmacovigilance, Dupuytren University Hospital (CHU Dupuytren), Limoges, France.
Cyrielle CoddePharmacology & Transplantation, INSERM U1248, University of Limoges, Limoges, France.
David BoutoilleINSERM, Infectious and Tropical Diseases Department, CIC 1413, Nantes University, Nantes University Hospital, Nantes, France.
Pierre MarquetDepartment of Pharmacology, Toxicology and Pharmacovigilance, Dupuytren University Hospital (CHU Dupuytren), Limoges, France.
Jean-Baptiste WoillardDepartment of Pharmacology, Toxicology and Pharmacovigilance, Dupuytren University Hospital (CHU Dupuytren), Limoges, France.ORCID 0000-0003-1695-0695

Funding

Agence Nationale de la Recherche ANR-22-PESN-0017
6 · The paper itself

Abstract

Dalbavancin is increasingly used off-label for prolonged therapy in gram-positive infections, but optimal repeat-dosing strategies remain undefined, and published population pharmacokinetic (popPK) models lack external validation in real-world cohorts. A popPK model was developed using routine therapeutic drug monitoring (TDM) data from 183 adults (406 concentrations) with gram-positive infections and externally validated in an independent cohort (

Indexed as

Anti-Bacterial AgentsGram-Positive Bacterial InfectionsTeicoplaninAdultAgedBayes TheoremDrug MonitoringFemaleHumansMaleMicrobial Sensitivity TestsMiddle AgedModels, BiologicalMonte Carlo MethodAnti-Bacterial AgentsdalbavancinTeicoplaninantimicrobial stewardshipdalbavancingram-positive infectionindividualized dosingpopulation pharmacokinetics

Identifiers

PMID42363831
PMCPMC13436002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.